Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

Journal of Medicinal Chemistry

Volumn 59, Issue 19, 2016, Pages 8667-8684

  Sonawane, Yogesh A ^a   Taylor, Margaret A ^a   Napoleon, John Victor ^a   Rana, Sandeep ^a   Contreras, Jacob I ^a   Natarajan, Amarnath ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVONOID; MACROCYCLIC COMPOUND; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZINE DERIVATIVE;

CANCER THERAPY; CELL STRUCTURE; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME STRUCTURE; HUMAN; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR MODEL; NEOPLASMS; PROCEDURES;

ANIMALS; CYCLIN-DEPENDENT KINASE 9; DRUG DISCOVERY; FLAVONOIDS; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN KINASE INHIBITORS; PURINES; PYRAZOLES; PYRIMIDINES; TRIAZINES;

EID: 84991380513     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00150     Document Type: Review

References (167)

1. Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors Trends Pharmacol. Sci. 2015, 36, 422-439 10.1016/j.tips.2015.04.005
2. Heathcote, D. A.; Patel, H.; Kroll, S. H.; Hazel, P.; Periyasamy, M.; Alikian, M.; Kanneganti, S. K.; Jogalekar, A. S.; Scheiper, B.; Barbazanges, M.; Blum, A.; Brackow, J.; Siwicka, A.; Pace, R. D.; Fuchter, M. J.; Snyder, J. P.; Liotta, D. C.; Freemont, P. S.; Aboagye, E. O.; Coombes, R. C.; Barrett, A. G.; Ali, S. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration J. Med. Chem. 2010, 53, 8508-8522 10.1021/jm100732t
3. Zheleva, D. Novel purine CDK inhibitors and their therapeutic potential. www.molonkol.org/-data/section-1/60.pdf, 2010.
4. Conroy, A.; Stockett, D. E.; Walker, D.; Arkin, M. R.; Hoch, U.; Fox, J. A.; Hawtin, R. E. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples Cancer Chemother. Pharmacol. 2009, 64, 723-732 10.1007/s00280-008-0921-5
5. Siemeister, G.; Lucking, U.; Wengner, A. M.; Lienau, P.; Steinke, W.; Schatz, C.; Mumberg, D.; Ziegelbauer, K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application Mol. Cancer Ther. 2012, 11, 2265-2273 10.1158/1535-7163.MCT-12-0286
6. Byth, K. F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R. W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts Mol. Cancer Ther. 2009, 8, 1856-1866 10.1158/1535-7163.MCT-08-0836
7. Joshi, K. S.; Rathos, M. J.; Joshi, R. D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 Mol. Cancer Ther. 2007, 6, 918-925 10.1158/1535-7163.MCT-06-0613
8. Joshi, K. S.; Padgaonkar, A.; Rathos, M. J.; Wagh, V.; Manohar, S.; Bhatia, D.; Damre, A.; Sivakumar, M.; Sharma, S. P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity Cancer Res. 2012, 72, 3054 10.1158/1538-7445.AM2012-3054
9. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M. P.; Doll, R.; Nomeir, A.; Windsor, W.; Fischmann, T.; Wang, Y.; Oft, M.; Chen, T.; Kirschmeier, P.; Lees, E. M. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor Mol. Cancer Ther. 2010, 9, 2344-2353 10.1158/1535-7163.MCT-10-0324
10. Zhang, C. C.; Kephart, S.; McAlpine, I.; Nonomiya, J.; Higgins, J.; Arango, M. E.; Yan, E.; Knighton, D.; Ferre, R. A.; Tikhe, J.; Verkhivker, G.; Xu, M.; Romines, W.; Palmer, C.; Park, J.; Reich, S.; Chong, W.; Li, L.; Los, G.; Lewis, C. AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity Cancer Res. 2005, 65, 1045
11. Gelbert, L. M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; Del Prado, M.; Lallena, M. J.; Torres, R.; Ajamie, R. T.; Wishart, G. N.; Flack, R. S.; Neubauer, B. L.; Young, J.; Chan, E. M.; Iversen, P.; Cronier, D.; Kreklau, E.; de Dios, A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest. New Drugs 2014, 32, 825-837 10.1007/s10637-014-0120-7
12. Beaver, J. A.; Amiri-Kordestani, L.; Charlab, R.; Chen, W.; Palmby, T.; Tilley, A.; Zirkelbach, J. F.; Yu, J.; Liu, Q.; Zhao, L.; Crich, J.; Chen, X. H.; Hughes, M.; Bloomquist, E.; Tang, S.; Sridhara, R.; Kluetz, P. G.; Kim, G.; Ibrahim, A.; Pazdur, R.; Cortazar, P. FDA Approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer Clin. Cancer Res. 2015, 21, 4760-4766 10.1158/1078-0432.CCR-15-1185
13. Fry, D. W.; Harvey, P. J.; Keller, P. R.; Elliott, W. L.; Meade, M.; Trachet, E.; Albassam, M.; Zheng, X.; Leopold, W. R.; Pryer, N. K.; Toogood, P. L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol. Cancer Ther. 2004, 3, 1427-1438
14. Toogood, P. L.; Harvey, P. J.; Repine, J. T.; Sheehan, D. J.; VanderWel, S. N.; Zhou, H.; Keller, P. R.; McNamara, D. J.; Sherry, D.; Zhu, T.; Brodfuehrer, J.; Choi, C.; Barvian, M. R.; Fry, D. W. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6 J. Med. Chem. 2005, 48, 2388-2406 10.1021/jm049354h
15. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer Nat. Rev. Drug Discovery 2009, 8, 547-566 10.1038/nrd2907
16. Asghar, U.; Witkiewicz, A. K.; Turner, N. C.; Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discovery 2015, 14, 130-146 10.1038/nrd4504
17. De Luca, A.; De Falco, M.; Baldi, A.; Paggi, M. G. Cyclin T: three forms for different roles in physiological and pathological functions J. Cell. Physiol. 2003, 194, 101-107 10.1002/jcp.10196
18. De Luca, A.; Russo, P.; Severino, A.; Baldi, A.; Battista, T.; Cavallotti, I.; De Luca, L.; Baldi, F.; Giordano, A.; Paggi, M. G. Pattern of expression of cyclin T1 in human tissues J. Histochem. Cytochem. 2001, 49, 685-692 10.1177/002215540104900602
19. De Luca, A.; Tosolini, A.; Russo, P.; Severino, A.; Baldi, A.; De Luca, L.; Cavallotti, I.; Baldi, F.; Giordano, A.; Testa, J. R.; Paggi, M. G. Cyclin T2a gene maps on human chromosome 2q21 J. Histochem. Cytochem. 2001, 49, 693-698 10.1177/002215540104900603
20. Edwards, M. C.; Wong, C.; Elledge, S. J. Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity Mol. Cell. Biol. 1998, 18, 4291-4300 10.1128/MCB.18.7.4291
21. Liu, H.; Herrmann, C. H. Differential localization and expression of the Cdk9 42k and 55k isoforms J. Cell. Physiol. 2005, 203, 251-260 10.1002/jcp.20224
22. Shore, S. M.; Byers, S. A.; Dent, P.; Price, D. H. Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms Gene 2005, 350, 51-58 10.1016/j.gene.2005.01.015
23. Li, Q.; Price, J. P.; Byers, S. A.; Cheng, D.; Peng, J.; Price, D. H. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186 J. Biol. Chem. 2005, 280, 28819-28826 10.1074/jbc.M502712200
24. Ramakrishnan, R.; Rice, A. P. Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway J. Cell. Physiol. 2012, 227, 609-617 10.1002/jcp.22760
25. Devaiah, B. N.; Singer, D. S. Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation J. Biol. Chem. 2012, 287, 38755-38766 10.1074/jbc.M112.412015
26. Larochelle, S.; Amat, R.; Glover-Cutter, K.; Sanso, M.; Zhang, C.; Allen, J. J.; Shokat, K. M.; Bentley, D. L.; Fisher, R. P. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II Nat. Struct. Mol. Biol. 2012, 19, 1108-1115 10.1038/nsmb.2399
27. Lu, H.; Xue, Y.; Yu, G. K.; Arias, C.; Lin, J.; Fong, S.; Faure, M.; Weisburd, B.; Ji, X.; Mercier, A.; Sutton, J.; Luo, K.; Gao, Z.; Zhou, Q. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism eLife 2015, 4, e06535 10.7554/eLife.06535
28. Gu, Y.; Rosenblatt, J.; Morgan, D. O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15 EMBO J. 1992, 11, 3995-4005
29. Wang, Y.; Dow, E. C.; Liang, Y. Y.; Ramakrishnan, R.; Liu, H.; Sung, T. L.; Lin, X.; Rice, A. P. Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-loop J. Biol. Chem. 2008, 283, 33578-33584 10.1074/jbc.M807495200
30. Peng, J.; Zhu, Y.; Milton, J. T.; Price, D. H. Identification of multiple cyclin subunits of human P-TEFb Genes Dev. 1998, 12, 755-762 10.1101/gad.12.5.755
31. O'Keeffe, B.; Fong, Y.; Chen, D.; Zhou, S.; Zhou, Q. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription J. Biol. Chem. 2000, 275, 279-287 10.1074/jbc.275.1.279
32. Baumli, S.; Lolli, G.; Lowe, E. D.; Troiani, S.; Rusconi, L.; Bullock, A. N.; Debreczeni, J. E.; Knapp, S.; Johnson, L. N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation EMBO J. 2008, 27, 1907-1918 10.1038/emboj.2008.121
33. Bosken, C. A.; Farnung, L.; Hintermair, C.; Merzel Schachter, M.; Vogel-Bachmayr, K.; Blazek, D.; Anand, K.; Fisher, R. P.; Eick, D.; Geyer, M. The structure and substrate specificity of human Cdk12/Cyclin K Nat. Commun. 2014, 5, 3505 10.1038/ncomms4505
34. Baek, K.; Brown, R. S.; Birrane, G.; Ladias, J. A. Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9 J. Mol. Biol. 2007, 366, 563-573 10.1016/j.jmb.2006.11.057
35. Simone, C.; Stiegler, P.; Bagella, L.; Pucci, B.; Bellan, C.; De Falco, G.; De Luca, A.; Guanti, G.; Puri, P. L.; Giordano, A. Activation of MyoD-dependent transcription by cdk9/cyclin T2 Oncogene 2002, 21, 4137-4148 10.1038/sj.onc.1205493
36. Liu, H.; Herrmann, C. H.; Chiang, K.; Sung, T. L.; Moon, S. H.; Donehower, L. A.; Rice, A. P. 55K isoform of CDK9 associates with Ku70 and is involved in DNA repair Biochem. Biophys. Res. Commun. 2010, 397, 245-250 10.1016/j.bbrc.2010.05.092
37. Yu, D. S.; Zhao, R.; Hsu, E. L.; Cayer, J.; Ye, F.; Guo, Y.; Shyr, Y.; Cortez, D. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response EMBO Rep. 2010, 11, 876-882 10.1038/embor.2010.153
38. Peterlin, B. M.; Brogie, J. E.; Price, D. H. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription Wiley Interdiscip. Rev. RNA 2012, 3, 92-103 10.1002/wrna.106
39. Nekhai, S.; Petukhov, M.; Breuer, D. Regulation of CDK9 activity by phosphorylation and dephosphorylation BioMed Res. Int. 2014, 2014, 964964 10.1155/2014/964964
40. Corden, J. L.; Cadena, D. L.; Ahearn, J. M., Jr.; Dahmus, M. E. A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II Proc. Natl. Acad. Sci. U. S. A. 1985, 82, 7934-7938 10.1073/pnas.82.23.7934
41. Ramanathan, Y.; Rajpara, S. M.; Reza, S. M.; Lees, E.; Shuman, S.; Mathews, M. B.; Pe'ery, T. Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences J. Biol. Chem. 2001, 276, 10913-10920 10.1074/jbc.M010975200
42. Chapman, R. D.; Heidemann, M.; Albert, T. K.; Mailhammer, R.; Flatley, A.; Meisterernst, M.; Kremmer, E.; Eick, D. Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7 Science 2007, 318, 1780-1782 10.1126/science.1145977
43. Glover-Cutter, K.; Larochelle, S.; Erickson, B.; Zhang, C.; Shokat, K.; Fisher, R. P.; Bentley, D. L. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II Mol. Cell. Biol. 2009, 29, 5455-5464 10.1128/MCB.00637-09
44. Akhtar, M. S.; Heidemann, M.; Tietjen, J. R.; Zhang, D. W.; Chapman, R. D.; Eick, D.; Ansari, A. Z. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II Mol. Cell 2009, 34, 387-393 10.1016/j.molcel.2009.04.016
45. Hsin, J. P.; Sheth, A.; Manley, J. L. RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3′ end processing Science 2011, 334, 683-686 10.1126/science.1206034
46. Czudnochowski, N.; Bosken, C. A.; Geyer, M. Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition Nat. Commun. 2012, 3, 842 10.1038/ncomms1846
47. Chao, S. H.; Fujinaga, K.; Marion, J. E.; Taube, R.; Sausville, E. A.; Senderowicz, A. M.; Peterlin, B. M.; Price, D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J. Biol. Chem. 2000, 275, 28345-28348 10.1074/jbc.C000446200
48. Wang, S.; Fischer, P. M. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol. Sci. 2008, 29, 302-313 10.1016/j.tips.2008.03.003
49. Bose, P.; Simmons, G. L.; Grant, S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies Expert Opin. Invest. Drugs 2013, 22, 723-738 10.1517/13543784.2013.789859
50. Wang, S.; Griffiths, G.; Midgley, C. A.; Barnett, A. L.; Cooper, M.; Grabarek, J.; Ingram, L.; Jackson, W.; Kontopidis, G.; McClue, S. J.; McInnes, C.; McLachlan, J.; Meades, C.; Mezna, M.; Stuart, I.; Thomas, M. P.; Zheleva, D. I.; Lane, D. P.; Jackson, R. C.; Glover, D. M.; Blake, D. G.; Fischer, P. M. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents Chem. Biol. 2010, 17, 1111-1121 10.1016/j.chembiol.2010.07.016
51. Lemke, J.; von Karstedt, S.; Abd El Hay, M.; Conti, A.; Arce, F.; Montinaro, A.; Papenfuss, K.; El-Bahrawy, M. A.; Walczak, H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1 Cell Death Differ. 2014, 21, 491-502 10.1038/cdd.2013.179
52. Huang, C. H.; Lujambio, A.; Zuber, J.; Tschaharganeh, D. F.; Doran, M. G.; Evans, M. J.; Kitzing, T.; Zhu, N.; de Stanchina, E.; Sawyers, C. L.; Armstrong, S. A.; Lewis, J. S.; Sherr, C. J.; Lowe, S. W. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma Genes Dev. 2014, 28, 1800-1814 10.1101/gad.244368.114
53. Wang, Z. Q.; Johnson, C. L.; Kumar, A.; Molkentine, D. P.; Molkentine, J. M.; Rabin, T.; Mason, K. A.; Milas, L.; Raju, U. Inhibition of P-TEFb by DRB suppresses SIRT1/CK2alpha pathway and enhances radiosensitivity of human cancer cells Anticancer Res. 2014, 34, 6981-6989
54. Storch, K.; Cordes, N. The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells Int. J. Oncol. 2015, 48, 191-198 10.3892/ijo.2015.3246
55. Lam, F.; Abbas, A. Y.; Shao, H.; Teo, T.; Adams, J.; Li, P.; Bradshaw, T. D.; Fischer, P. M.; Walsby, E.; Pepper, C. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73 Oncotarget 2014, 5, 7691-7704 10.18632/oncotarget.2296
56. Garriga, J.; Xie, H.; Obradovic, Z.; Grana, X. Selective control of gene expression by CDK9 in human cells J. Cell. Physiol. 2010, 222, 200-208 10.1002/jcp.21938
57. Garriga, J.; Grana, X. CDK9 inhibition strategy defines distinct sets of target genes BMC Res. Notes 2014, 7, 301 10.1186/1756-0500-7-301
58. Nguyen, V. T.; Kiss, T.; Michels, A. A.; Bensaude, O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes Nature 2001, 414, 322-325 10.1038/35104581
59. Tian, B.; Zhao, Y.; Kalita, M.; Edeh, C. B.; Paessler, S.; Casola, A.; Teng, M. N.; Garofalo, R. P.; Brasier, A. R. CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells J. Virol. 2013, 87, 7075-7092 10.1128/JVI.03399-12
60. Yang, J.; Zhao, Y.; Kalita, M.; Li, X.; Jamaluddin, M.; Tian, B.; Edeh, C. B.; Wiktorowicz, J. E.; Kudlicki, A.; Brasier, A. R. Systematic determination of human cyclin dependent kinase (CDK)-9 interactome identifies novel functions in RNA splicing mediated by the DEAD box (DDX)-5/17 RNA helicases Mol. Cell. Proteomics 2015, 14, 2701-2721 10.1074/mcp.M115.049221
61. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1039-1045 10.1038/nbt.2017
62. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.; Detivaud, L.; Leclerc, S. et al. Inhibition of cyclin-dependent kinases by purine analogues Eur. J. Biochem. 1994, 224, 771-786 10.1111/j.1432-1033.1994.00771.x
63. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine Eur. J. Biochem. 1997, 243, 518-526 10.1111/j.1432-1033.1997.0518a.x
64. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors Chem. Biol. 1999, 6, 361-375 10.1016/S1074-5521(99)80048-9
65. Te Poele, R. H.; Okorokov, A. L.; Joel, S. P. RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells Oncogene 1999, 18, 5765-5772 10.1038/sj.onc.1202961
66. McInnes, C.; Wang, S.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.; Lane, D. P.; Fischer, P. M. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors Chem. Biol. 2004, 11, 525-534 10.1016/j.chembiol.2004.03.022
67. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S. Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity J. Med. Chem. 2004, 47, 1662-1675 10.1021/jm0309957
68. Cai, D.; Byth, K. F.; Shapiro, G. I. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9 Cancer Res. 2006, 66, 435-444 10.1158/0008-5472.CAN-05-1769
69. Krystof, V.; Cankar, P.; Frysova, I.; Slouka, J.; Kontopidis, G.; Dzubak, P.; Hajduch, M.; Srovnal, J.; de Azevedo, W. F., Jr.; Orsag, M.; Paprskarova, M.; Rolcik, J.; Latr, A.; Fischer, P. M.; Strnad, M. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects J. Med. Chem. 2006, 49, 6500-6509 10.1021/jm0605740
70. Shimamura, T.; Shibata, J.; Kurihara, H.; Mita, T.; Otsuki, S.; Sagara, T.; Hirai, H.; Iwasawa, Y. Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9 Bioorg. Med. Chem. Lett. 2006, 16, 3751-3754 10.1016/j.bmcl.2006.04.048
71. Sondhi, S. M.; Singh, N.; Kumar, A.; Lozach, O.; Meijer, L. Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases Bioorg. Med. Chem. 2006, 14, 3758-3765 10.1016/j.bmc.2006.01.054
72. Lin, R.; Chiu, G.; Yu, Y.; Connolly, P. J.; Li, S.; Lu, Y.; Adams, M.; Fuentes-Pesquera, A. R.; Emanuel, S. L.; Greenberger, L. M. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4557-4561 10.1016/j.bmcl.2007.05.092
73. Jones, C. D.; Andrews, D. M.; Barker, A. J.; Blades, K.; Daunt, P.; East, S.; Geh, C.; Graham, M. A.; Johnson, K. M.; Loddick, S. A.; McFarland, H. M.; McGregor, A.; Moss, L.; Rudge, D. A.; Simpson, P. B.; Swain, M. L.; Tam, K. Y.; Tucker, J. A.; Walker, M. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing Bioorg. Med. Chem. Lett. 2008, 18, 6369-6373 10.1016/j.bmcl.2008.10.102
74. Jain, S. K.; Bharate, S. B.; Vishwakarma, R. A. Cyclin-dependent kinase inhibition by flavoalkaloids Mini-Rev. Med. Chem. 2012, 12, 632-649 10.2174/138955712800626683
75. Rath, S. L.; Senapati, S. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design PLoS One 2013, 8, e73836 10.1371/journal.pone.0073836
76. Shao, H.; Shi, S.; Huang, S.; Hole, A. J.; Abbas, A. Y.; Baumli, S.; Liu, X.; Lam, F.; Foley, D. W.; Fischer, P. M.; Noble, M.; Endicott, J. A.; Pepper, C.; Wang, S. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities J. Med. Chem. 2013, 56, 640-659 10.1021/jm301475f
77. Reznickova, E.; Weitensteiner, S.; Havlicek, L.; Jorda, R.; Gucky, T.; Berka, K.; Bazgier, V.; Zahler, S.; Krystof, V.; Strnad, M. Characterization of a pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases 2 and 5 and aurora A with pro-apoptotic and anti-angiogenic activity in vitro Chem. Biol. Drug Des. 2015, 86, 1528-1540 10.1111/cbdd.12618
78. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 J. Natl. Cancer Inst. 1992, 84, 1736-1740 10.1093/jnci/84.22.1736
79. Worland, P. J.; Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Sartor, O.; Sausville, E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity Biochem. Pharmacol. 1993, 46, 1831-1840 10.1016/0006-2952(93)90590-S
80. Carlson, B. A.; Dubay, M. M.; Sausville, E. A.; Brizuela, L.; Worland, P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res. 1996, 56, 2973-2978
81. Drees, M.; Dengler, W. A.; Roth, T.; Labonte, H.; Mayo, J.; Malspeis, L.; Grever, M.; Sausville, E. A.; Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells Clin. Cancer Res. 1997, 3, 273-279
82. Shapiro, G. I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol Clin. Cancer Res. 2004, 10, 4270s-4275s 10.1158/1078-0432.CCR-040020
83. Shapiro, G. I.; Supko, J. G.; Patterson, A.; Lynch, C.; Lucca, J.; Zacarola, P. F.; Muzikansky, A.; Wright, J. J.; Lynch, T. J., Jr.; Rollins, B. J. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer Clin. Cancer. Res. 2001, 7, 1590-1599
84. Rai, K. R.; Holland, J. F.; Glidewell, O. J.; Weinberg, V.; Brunner, K.; Obrecht, J. P.; Preisler, H. D.; Nawabi, I. W.; Prager, D.; Carey, R. W.; Cooper, M. R.; Haurani, F.; Hutchison, J. L.; Silver, R. T.; Falkson, G.; Wiernik, P.; Hoagland, H. C.; Bloomfield, C. D.; James, G. W.; Gottlieb, A.; Ramanan, S. V.; Blom, J.; Nissen, N. I.; Bank, A.; Ellison, R. R.; Kung, F.; Henry, P.; McIntyre, O. R.; Kaan, S. K. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B Blood 1981, 58, 1203-1212
85. Tefferi, A.; Letendre, L. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia J. Clin. Oncol. 2012, 30, 2425-2428 10.1200/JCO.2011.38.9601
86. Karp, J. E.; Smith, B. D.; Levis, M. J.; Gore, S. D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R. J.; Wright, J. J.; Colevas, A. D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia Clin. Cancer Res. 2007, 13, 4467-4473 10.1158/1078-0432.CCR-07-0381
87. Karp, J. E.; Garrett-Mayer, E.; Estey, E. H.; Rudek, M. A.; Smith, B. D.; Greer, J. M.; Drye, D. M.; Mackey, K.; Dorcy, K. S.; Gore, S. D.; Levis, M. J.; McDevitt, M. A.; Carraway, H. E.; Pratz, K. W.; Gladstone, D. E.; Showel, M. M.; Othus, M.; Doyle, L. A.; Wright, J. J.; Pagel, J. M. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia Haematologica 2012, 97, 1736-1742 10.3324/haematol.2012.062539
88. Zeidner, J. F.; Foster, M. C.; Blackford, A. L.; Litzow, M. R.; Morris, L. E.; Strickland, S. A.; Lancet, J. E.; Bose, P.; Levy, M. Y.; Tibes, R.; Gojo, I.; Gocke, C. D.; Rosner, G. L.; Little, R. F.; Wright, J. J.; Doyle, L. A.; Smith, B. D.; Karp, J. E. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia Haematologica 2015, 100, 1172-1179 10.3324/haematol.2015.125849
89. Bose, P.; Grant, S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML Leuk. Res. 2014, 38, 862-865 10.1016/j.leukres.2014.06.007
90. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy Oncogene 2000, 19, 6600-6606 10.1038/sj.onc.1204085
91. Schwartz, G. K.; O'Reilly, E.; Ilson, D.; Saltz, L.; Sharma, S.; Tong, W.; Maslak, P.; Stoltz, M.; Eden, L.; Perkins, P.; Endres, S.; Barazzoul, J.; Spriggs, D.; Kelsen, D. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors J. Clin. Oncol. 2002, 20, 2157-2170 10.1200/JCO.2002.08.080
92. Dai, Y.; Rahmani, M.; Pei, X. Y.; Dent, P.; Grant, S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms Blood 2004, 104, 509-518 10.1182/blood-2003-12-4121
93. Luke, J. J.; D'Adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Maki, R. G.; de Stanchina, E.; Musi, E.; Singer, S.; Schwartz, G. K. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial Clin. Cancer Res. 2012, 18, 2638-2647 10.1158/1078-0432.CCR-11-3203
94. De Azevedo, W. F., Jr.; Mueller-Dieckmann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 2735-2740 10.1073/pnas.93.7.2735
95. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 1998, 281, 533-538 10.1126/science.281.5376.533
96. Carlson, B.; Lahusen, T.; Singh, S.; Loaiza-Perez, A.; Worland, P. J.; Pestell, R.; Albanese, C.; Sausville, E. A.; Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol Cancer Res. 1999, 59, 4634-4641
97. Chao, S. H.; Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo J. Biol. Chem. 2001, 276, 31793-31799 10.1074/jbc.M102306200
98. Hole, A. J.; Baumli, S.; Shao, H.; Shi, S.; Huang, S.; Pepper, C.; Fischer, P. M.; Wang, S.; Endicott, J. A.; Noble, M. E. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity J. Med. Chem. 2013, 56, 660-670 10.1021/jm301495v
99. Biglione, S.; Byers, S. A.; Price, J. P.; Nguyen, V. T.; Bensaude, O.; Price, D. H.; Maury, W. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex Retrovirology 2007, 4, 47 10.1186/1742-4690-4-47
100. Ali, A.; Ghosh, A.; Nathans, R. S.; Sharova, N.; O'Brien, S.; Cao, H.; Stevenson, M.; Rana, T. M. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication ChemBioChem 2009, 10, 2072-2080 10.1002/cbic.200900303
101. Manohar, S. M.; Rathos, M. J.; Sonawane, V.; Rao, S. V.; Joshi, K. S. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription Leuk. Res. 2011, 35, 821-830 10.1016/j.leukres.2010.12.010
102. Joshi, K. S.; Rathos, M. J.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H. H.; Sharma, S. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models Mol. Cancer Ther. 2007, 6, 926-934 10.1158/1535-7163.MCT-06-0614
103. Shirsath, N. P.; Manohar, S. M.; Joshi, K. S. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines Mol. Cancer 2012, 11, 77 10.1186/1476-4598-11-77
104. Raje, N.; Hideshima, T.; Mukherjee, S.; Raab, M.; Vallet, S.; Chhetri, S.; Cirstea, D.; Pozzi, S.; Mitsiades, C.; Rooney, M.; Kiziltepe, T.; Podar, K.; Okawa, Y.; Ikeda, H.; Carrasco, R.; Richardson, P. G.; Chauhan, D.; Munshi, N. C.; Sharma, S.; Parikh, H.; Chabner, B.; Scadden, D.; Anderson, K. C. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma Leukemia 2009, 23, 961-970 10.1038/leu.2008.378
105. Parker, W. B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer Chem. Rev. 2009, 109, 2880-2893 10.1021/cr900028p
106. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P. M.; Walkinshaw, M. D. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop Structure 2003, 11, 399-410 10.1016/S0969-2126(03)00060-1
107. Lukasik, P. M.; Elabar, S.; Lam, F.; Shao, H.; Liu, X.; Abbas, A. Y.; Wang, S. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents Eur. J. Med. Chem. 2012, 57, 311-322 10.1016/j.ejmech.2012.09.034
108. Shao, H.; Shi, S.; Foley, D. W.; Lam, F.; Abbas, A. Y.; Liu, X.; Huang, S.; Jiang, X.; Baharin, N.; Fischer, P. M.; Wang, S. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents Eur. J. Med. Chem. 2013, 70, 447-455 10.1016/j.ejmech.2013.08.052
109. Baumli, S.; Hole, A. J.; Noble, M. E.; Endicott, J. A. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508 ACS Chem. Biol. 2012, 7, 811-816 10.1021/cb2004516
110. Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L. Novel, selective CDK9 inhibitors for the treatment of HIV infection Curr. Med. Chem. 2011, 18, 342-358 10.2174/092986711794839188
111. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591 10.1021/jm1013693
112. Albert, T. K.; Rigault, C.; Eickhoff, J.; Baumgart, K.; Antrecht, C.; Klebl, B.; Mittler, G.; Meisterernst, M. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor Br. J. Pharmacol. 2014, 171, 55-68 10.1111/bph.12408
113. Nemeth, G.; Greff, Z.; Sipos, A.; Varga, Z.; Szekely, R.; Sebestyen, M.; Jaszay, Z.; Beni, S.; Nemes, Z.; Pirat, J. L.; Volle, J. N.; Virieux, D.; Gyuris, A.; Kelemenics, K.; Ay, E.; Minarovits, J.; Szathmary, S.; Keri, G.; Orfi, L. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors J. Med. Chem. 2014, 57, 3939-3965 10.1021/jm401742r
114. Hibino, S.; Choshi, T. Simple indole alkaloids and those with a nonrearranged monoterpenoid unit Nat. Prod. Rep. 2002, 19, 148-180 10.1039/b007740m
115. Franco, L. H.; Joffé, E. B. d. K.; Puricelli, L.; Tatian, M.; Seldes, A. M.; Palermo, J. A. Indole alkaloids from the tunicate aplidium meridianum J. Nat. Prod. 1998, 61, 1130-1132 10.1021/np970493u
116. Fresneda, P. M.; Molina, P.; Delgado, S.; Bleda, J. A. Synthetic studies towards the 2-aminopyrimidine alkaloids variolins and meridianins from marine origin Tetrahedron Lett. 2000, 41, 4777-4780 10.1016/S0040-4039(00)00728-0
117. Jiang, B.; Yang, C.-g. Synthesis of indolylpyrimidiness via cross-coupling of indolylboronic acid with choropyrimidines: facile synthesis of meridianin D Heterocycles 2000, 53, 1489-1498 10.3987/COM-00-8890
118. Franco, L. H.; Palermo, J. A. Synthesis of 2-(pyrimidin-4-yl) indoles Chem. Pharm. Bull. 2003, 51, 975-977 10.1248/cpb.51.975
119. Gompel, M.; Leost, M.; Joffe, E. B. D. K.; Puricelli, L.; Franco, L. H.; Palermo, J.; Meijer, L. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum Bioorg. Med. Chem. Lett. 2004, 14, 1703-1707 10.1016/j.bmcl.2004.01.050
120. Perry, N. B.; Ettouati, L.; Litaudon, M.; Blunt, J. W.; Munro, M. H.; Parkin, S.; Hope, H. Alkaloids from the antarctic sponge Kirkpatrickia varialosa.: Part 1: Variolin B, a new antitumour and antiviral compound Tetrahedron 1994, 50, 3987-3992 10.1016/S0040-4020(01)89673-3
121. Trimurtulu, G.; Faulkner, D. J.; Perry, N. B.; Ettouati, L.; Litaudon, M.; Blunt, J. W.; Munro, M. H.; Jameson, G. B. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: Variolin A and N (3)-methyl tetrahydrovariolin B Tetrahedron 1994, 50, 3993-4000 10.1016/S0040-4020(01)89674-5
122. Anderson, R. J.; Hill, J. B.; Morris, J. C. Concise total syntheses of variolin B and deoxyvariolin B J. Org. Chem. 2005, 70, 6204-6212 10.1021/jo050523v
123. Mendiola, J.; Baeza, A.; Alvarez-Builla, J.; Vaquero, J. J. Reaction of bromomethylazoles and tosylmethyl isocyanide. A novel heterocyclization method for the synthesis of the core of marine alkaloids variolins and related azolopyrimidines J. Org. Chem. 2004, 69, 4974-4983 10.1021/jo0358168
124. Ahaidar, A.; Fernández, D.; Danelón, G.; Cuevas, C.; Manzanares, I.; Albericio, F.; Joule, J. A.; álvarez, M. Total Syntheses of variolin B and deoxyvariolin B1 J. Org. Chem. 2003, 68, 10020-10029 10.1021/jo035332b
125. Molina, P.; Fresneda, P. M.; Delgado, S. Carbodiimide-mediated preparation of the tricyclic pyrido [3′, 2′: 4, 5] pyrrolo [1, 2-c] pyrimidine ring system and its application to the synthesis of the potent antitumoral marine alkaloid variolin B and analog J. Org. Chem. 2003, 68, 489-499 10.1021/jo026508x
126. Anderson, R. J.; Morris, J. C. Total synthesis of variolin B Tetrahedron Lett. 2001, 42, 8697-8699 10.1016/S0040-4039(01)01881-0
127. Echalier, A.; Bettayeb, K.; Ferandin, Y.; Lozach, O.; Clement, M.; Valette, A.; Liger, F.; Marquet, B.; Morris, J. C.; Endicott, J. A.; Joseph, B.; Meijer, L. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex J. Med. Chem. 2008, 51, 737-751 10.1021/jm700940h
128. Bettayeb, K.; Tirado, O. M.; Marionneau-Lambot, S.; Ferandin, Y.; Lozach, O.; Morris, J. C.; Mateo-Lozano, S.; Drueckes, P.; Schächtele, C.; Kubbutat, M. H. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases Cancer Res. 2007, 67, 8325-8334 10.1158/0008-5472.CAN-07-1826
129. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery - an underexploited structural class Nat. Rev. Drug Discovery 2008, 7, 608-624 10.1038/nrd2590
130. Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties Leukemia 2012, 26, 236-243 10.1038/leu.2011.218
131. álvarez-Fernández, S.; Hernández-García, S.; Chen, X.; Ocio, E. M.; Paiva, B.; Meshaw, K. R.; Cheatham, L. A.; Burrows, F.; San-Miguel, J. F.; Pandiella, A. Antimyeloma action of the multikinase inhibitor TG02 Blood 2010, 1655-1655
132. Abdul-Aziz, A.; Burrows, F.; Yu, N.; Russell, N. H.; Seedhouse, C. H.; Pallis, M. ABT-737 and ABT-199 complement the multikinase inhibitor TG02 to induce apoptosis in acute myeloid leukemia cells Cancer Res. 2014, 74, 4536-4536 10.1158/1538-7445.AM2014-4536
133. Paruch, K.; Dwyer, M. P.; Alvarez, C.; Brown, C.; Chan, T.-Y.; Doll, R. J.; Keertikar, K.; Knutson, C.; McKittrick, B.; Rivera, J. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases ACS Med. Chem. Lett. 2010, 1, 204-208 10.1021/ml100051d
134. Flynn, J.; Jones, J.; Johnson, A. J.; Andritsos, L.; Maddocks, K.; Jaglowski, S.; Hessler, J.; Grever, M. R.; Im, E.; Zhou, H. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia Leukemia 2015, 29, 1524-1529 10.1038/leu.2015.31
135. Guha, M. Cyclin-dependent kinase inhibitors move into phase III Nat. Rev. Drug Discovery 2012, 11, 892-894 10.1038/nrd3908
136. Yin, T.; Lallena, M. J.; Kreklau, E. L.; Fales, K. R.; Carballares, S.; Torrres, R.; Wishart, G. N.; Ajamie, R. T.; Cronier, D. M.; Iversen, P. W.; Meier, T. I.; Foreman, R. T.; Zeckner, D.; Sissons, S. E.; Halstead, B. W.; Lin, A. B.; Donoho, G. P.; Qian, Y.; Li, S.; Wu, S.; Aggarwal, A.; Ye, X. S.; Starling, J. J.; Gaynor, R. B.; de Dios, A.; Du, J. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models Mol. Cancer Ther. 2014, 13, 1442-1456 10.1158/1535-7163.MCT-13-0849
137. Pevarello, P.; Brasca, M. G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding J. Med. Chem. 2004, 47, 3367-3380 10.1021/jm031145u
138. Pevarello, P.; Brasca, M. G.; Orsini, P.; Traquandi, G.; Longo, A.; Nesi, M.; Orzi, F.; Piutti, C.; Sansonna, P.; Varasi, M.; Cameron, A.; Vulpetti, A.; Roletto, F.; Alzani, R.; Ciomei, M.; Albanese, C.; Pastori, W.; Marsiglio, A.; Pesenti, E.; Fiorentini, F.; Bischoff, J. R.; Mercurio, C. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization J. Med. Chem. 2005, 48, 2944-2956 10.1021/jm0408870
139. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design J. Med. Chem. 2008, 51, 4986-4999 10.1021/jm800382h
140. Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition Oncogene 2010, 29, 2325-2336 10.1038/onc.2009.510
141. Squires, M. S.; Feltell, R. E.; Wallis, N. G.; Lewis, E. J.; Smith, D.-M.; Cross, D. M.; Lyons, J. F.; Thompson, N. T. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Mol. Cancer Ther. 2009, 8, 324-332 10.1158/1535-7163.MCT-08-0890
142. van der Biessen, D. A.; Burger, H.; de Bruijn, P.; Lamers, C. H.; Naus, N.; Loferer, H.; Wiemer, E. A.; Mathijssen, R. H.; de Jonge, M. J. Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumors Clin. Cancer Res. 2014, 20, 4776-4783 10.1158/1078-0432.CCR-14-0325
143. Cirstea, D.; Hideshima, T.; Santo, L.; Eda, H.; Mishima, Y.; Nemani, N.; Hu, Y.; Mimura, N.; Cottini, F.; Gorgun, G. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and-independent anti-multiple myeloma activity through inhibition of transcriptional CDKs Leukemia 2013, 27, 2366-2375 10.1038/leu.2013.194
144. Kaufmann, S. H.; Karp, J. E.; Svingen, P. A.; Krajewski, S.; Burke, P. J.; Gore, S. D.; Reed, J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse Blood 1998, 91, 991-1000
145. Glaser, S. P.; Lee, E. F.; Trounson, E.; Bouillet, P.; Wei, A.; Fairlie, W. D.; Izon, D. J.; Zuber, J.; Rappaport, A. R.; Herold, M. J.; Alexander, W. S.; Lowe, S. W.; Robb, L.; Strasser, A. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia Genes Dev. 2012, 26, 120-125 10.1101/gad.182980.111
146. Thomas, D.; Powell, J. A.; Vergez, F.; Segal, D. H.; Nguyen, N. Y.; Baker, A.; Teh, T. C.; Barry, E. F.; Sarry, J. E.; Lee, E. M.; Nero, T. L.; Jabbour, A. M.; Pomilio, G.; Green, B. D.; Manenti, S.; Glaser, S. P.; Parker, M. W.; Lopez, A. F.; Ekert, P. G.; Lock, R. B.; Huang, D. C.; Nilsson, S. K.; Recher, C.; Wei, A. H.; Guthridge, M. A. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription Blood 2013, 122, 738-748 10.1182/blood-2012-08-447441
147. Phillipson, L. J.; Segal, D. H.; Nero, T. L.; Parker, M. W.; Wan, S. S.; de Silva, M.; Guthridge, M. A.; Wei, A. H.; Burns, C. J. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9 Bioorg. Med. Chem. 2015, 23, 6280-6296 10.1016/j.bmc.2015.08.035
148. Barsanti, P. A.; Chen, Z.; Hu, C.; Jin, X.; Ng, S. C.; Pfister, K. B.; Sendzik, M.; Sutton, J. Bipyridines as CDK9 inhibitors and their preparation and use for the treatment of proliferative diseases. WO 2011026911, 2010.
149. Pfister, K. B.; Sendzik, M. Heteroaryl compounds as kinase inhibitors. WO 2011026917, 2011.
150. Heiser, U.; Niestroj, A. J.; Zeitlmann, L. Inhibitors of protein kinases. WO 2011110612, A1 2011.
151. Antonios-Mccrea, W. R.; Barsanti, P. A.; Hu, C.; Jin, X.; Pan, Y.; Pfister, K. B.; Martin, E. J.; Sendzik, M.; Sutton, J.; Wan, L. 3-(Aminoaryl)-pyridine compounds. WO 2012066070, 2012.
152. Dencker, D.; Husum, H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder Behav. Brain Res. 2010, 207, 78-83 10.1016/j.bbr.2009.09.040
153. Ng, F.; Hallam, K.; Lucas, N.; Berk, M. The role of lamotrigine in the management of bipolar disorder Neuropsychiatr. Dis. Treat. 2007, 3, 463-474
154. Bohlmann, R.; Bömer, U.; Gnoth, M. J.; Kosemund, D.; Lienau, P.; Lücking, U.; Rühter, G.; Scholz, A.; Schulz-Fademrecht, C.; Siemeister, G. Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines. WO 2012143399, 2012.
155. Bohlmann, R.; Bömer, U.; Gnoth, M. J.; Kosemund, D.; Lienau, P.; Lücking, U.; Rüther, G.; Scholz, A.; Schulz-Fademrecht, C.; Siemeister, G. 4-Aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group. US 20140315906, 2012.
156. Sharma, S.; Mehndiratta, S.; Kumar, S.; Singh, J.; Bedi, P. M. S.; Nepali, K. Purine analogues as kinase inhibitors: a review Recent Pat. Anti-Cancer Drug Discovery 2015, 10, 308-341 10.2174/1574892810666150617112230
157. Berberich, N.; Uhl, B.; Joore, J.; Schmerwitz, U. K.; Mayer, B. A.; Reichel, C. A.; Krombach, F.; Zahler, S.; Vollmar, A. M.; Fürst, R. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9 Br. J. Pharmacol. 2011, 163, 1086-1098 10.1111/j.1476-5381.2011.01309.x
158. Bettayeb, K.; Baunbæk, D.; Delehouze, C.; Loaëc, N.; Hole, A. J.; Baumli, S.; Endicott, J. A.; Douc-Rasy, S.; Bénard, J.; Oumata, N. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells Genes Cancer 2010, 1, 369-380 10.1177/1947601910369817
159. Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J.; Galons, H.; Meijer, L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases Oncogene 2008, 27, 5797-5807 10.1038/onc.2008.191
160. Vandenberg, C. J.; Cory, S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia Blood 2013, 121, 2285-2288 10.1182/blood-2013-01-475855
161. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 2006, 10, 389-399 10.1016/j.ccr.2006.08.027
162. Chen, S.; Dai, Y.; Harada, H.; Dent, P.; Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation Cancer Res. 2007, 67, 782-791 10.1158/0008-5472.CAN-06-3964
163. Lin, X.; Morgan-Lappe, S.; Huang, X.; Li, L.; Zakula, D. M.; Vernetti, L. A.; Fesik, S. W.; Shen, Y. "Seed" analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 Oncogene 2007, 26, 3972-3979 10.1038/sj.onc.1210166
164. Rajule, R.; Bryant, V. C.; Lopez, H.; Luo, X.; Natarajan, A. Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study Bioorg. Med. Chem. 2012, 20, 2227-2234 10.1016/j.bmc.2012.02.022
165. Contreras, J. I.; Natarajan, A. Chemical genetic screens to identify novel kinase inhibitor combination for cancer therapy. Unpublished results, 2016.
166. Hu, C.; Dadon, T.; Chenna, V.; Yabuuchi, S.; Bannerji, R.; Booher, R.; Strack, P.; Azad, N.; Nelkin, B. D.; Maitra, A. Combined inhibition of cyclin-dependent kinases (dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models Mol. Cancer Ther. 2015, 14, 1532-1539 10.1158/1535-7163.MCT-15-0028
167. Sumi, N. J.; Kuenzi, B. M.; Knezevic, C. E.; Remsing Rix, L. L.; Rix, U. Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer ACS Chem. Biol. 2015, 10, 2680-2686 10.1021/acschembio.5b00368